The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Johnson & Johnson wins U.S. FDA approval for RYBREVANT FASPRO in advanced head and neck cancer

Nov 6, 2026 02:03 (6h ago)

Verifying

Johnson & Johnson announced U.S. FDA approval of RYBREVANT FASPRO.
RYBREVANT FASPRO combines amivantamab and hyaluronidase-lpuj.
The therapy was described as the first and only dual-targeted treatment for advanced head and neck cancer.